Vertex executive Reshma Kewalramani filed notice of intent to sell 11,900 shares valued at about $6.31 million. The filing does not confirm a sale or explain why, so it does not change the company's outlook.
The notice does not explain her reason, and it does not confirm a completed sale. It reports no change to Vertex's products, sales, or operations, so it does not change the company's outlook.
Follow Vertex Pharmaceuticals (VRTX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VRTX